Raphael Pharmaceutical (RAPH) Total Debt (2020 - 2026)

Raphael Pharmaceutical has disclosed Total Debt across 7 years of filings, most recently posting $2.7 million for Q2 2026.

• In Q2 2026, Total Debt rose 340.17% year-over-year to $2.7 million; the TTM figure through Jun 2026 stood at $2.7 million (up 340.17% YoY), while the FY2025 annual figure was $1.9 million, up 287.53% from the prior year.
• Total Debt came in at $2.7 million for Q2 2026 at Raphael Pharmaceutical, up from $1.9 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $2.7 million in Q2 2026 to a low of $1000.0 in Q1 2022.
• Average Total Debt over 5 years is $486933.3, with a median of $76000.0 recorded in 2023.
• Year-over-year, Total Debt tumbled 72.73% in 2022 and jumped 2226.92% in 2025.
• Over 5 years, Total Debt stood at $6000.0 in 2022, then surged by 1166.67% to $76000.0 in 2023, then surged by 553.95% to $497000.0 in 2024, then surged by 287.53% to $1.9 million in 2025, then jumped by 38.27% to $2.7 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $2.7 million in Q2 2026, $1.9 million in Q4 2025, and $796000.0 in Q3 2025.